Skip to main content
. Author manuscript; available in PMC: 2017 Nov 28.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2012 Jul 12;85(3):686–692. doi: 10.1016/j.ijrobp.2012.05.023

Table 3.

PCSM Unadjusted Univariate and Adjusted Multivariate Fine and Gray Analysis

Univariate
Multivariate
P-Value HR (95% CI) P-Value HR (95% CI)
Age >65 vs ≤65 0.21 0.65 (0.34–1.26)
T-stage <0.001 1.40 (1.2–1.64) 0.033 1.22 (1.02–1.45)
Gleason score <0.001 1.98 (1.58–2.49) 0.004 1.51 (1.14–2.01)
PSA 0.4 1.01 (0.98–1.01)
ADT (yes vs no) 0.021 2.83 (1.17–6.83)
% Core Positivity (>50% vs ≤50%) <0.001 4.87 (2.41–9.85) 0.003 3.15 (1.49–6.67)
PSA density (>0.25 vs ≤0.25) 0.017 2.25 (1.15–4.37)

Abbreviations: ADT, androgen-deprivation therapy; CI, confidence interval; HR, hazard ration; PSA, prostate-specific antigen